REIMBURSEMENT/PAYMENT WORKSHEET



This worksheet is provided to assist your site of care in keeping track of your local payers' reimbursement/payment policies for Axumin® (fluciclovine F 18) injection. This is not a guide or instructions. The provider has the responsibility to ensure correct prior authorization, appeal, and denial policies are followed. Providers must ensure they accurately complete and submit necessary information to payers.

When performing pre-certifications or pre-determinations, you may fill out the template below as you determine the following: • Is Axumin being reimbursed/paid as a valid, billable code?

- Is Axumin bundled into the procedure code with no separate payment?
- Is Axumin considered "Experimental/Investigational"?
- Do the patient benefits cover Axumin?

Below is an example of a worksheet with insurer and plan type filled out, for your guidance:

INSURER	INSURER TYPE	PLAN NAME	ICD-10 Code(s)	AXUMIN BILLABLE (HCPCS)	PET SCAN BILLABLE (CPT)
Anthem	Medicare Advantage	BCBS of AL		No	Yes (78815)
United	Commercial			Yes	Yes (78815 & 78812)
AARP	Supplemental			Yes	Yes (78815 & 78812)
Geisinger	Secondary	Geisinger Gold		No	No

This information is subject to change as insurers update policies, contracts are revised, etc.

INSURER TYPE	PLAN NAME	ICD-10 Code(s)	AXUMIN BILLABLE (HCPCS)	PET SCAN BILLABLE (CPT)
		INSURER TYPE PLAN NAME	INSURER TYPE PLAN NAME ICD-10 Code(s) IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	INSURER TYPE PLAN NAME ICD-10 Code(s) AXUMIN BILLABLE (HCPCS) IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII



INSURER	INSURER TYPE	PLAN NAME	ICD-10 Code(s)	AXUMIN BILLABLE (HCPCS)	PET SCAN BILLABLE (CPT)

INDICATION

Axumin[®] (fluciclovine F18) injection is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.

IMPORTANT SAFETY INFORMATION

- Image interpretation errors can occur with Axumin PET imaging. A negative image does not rule out recurrent prostate cancer and a positive image does not confirm its presence. The performance of Axumin seems to be affected by PSA levels. Axumin uptake may occur with other cancers and benign prostatic hypertrophy in primary prostate cancer. Clinical correlation, which may include histopathological evaluation, is recommended.
- Hypersensitivity reactions, including anaphylaxis, may occur in patients who receive Axumin. Emergency resuscitation equipment and personnel should be immediately available.
- Axumin use contributes to a patient's overall long-term cumulative radiation exposure, which is associated with an increased risk of cancer. Safe handling practices should be used to minimize radiation exposure to the patient and health care providers.
- Adverse reactions were reported in ≤1% of subjects during clinical studies with Axumin. The most common adverse reactions were injection site pain, injection site erythema and dysgeusia.

To report suspected adverse reactions to Axumin, call 1-855-AXUMIN1 (1-855-298-6461) or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Full Axumin prescribing information is available at www.axumin.com.